events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally. The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total